Zhejiang Haichang Biotech Co., Ltd., Haichang Biotech is a global trailblazer committed to pushing the boundaries of biomedical technologies to better human health. With a strong emphasis on independent innovation and a solid global intellectual property right foundation, we drive the discovery and development of cutting-edge drug delivery systems. Our expertise lies in nucleic acid technologies. We actively contribute to the evolution of mRNA vaccine, small nucleic acid drugs, and complex injections.
Our broad product pipelines span various fields, encompassing infectious disease prevention, tumor immunotherapy, antitumor therapy, analgesia and more.
Headquartered in Hangzhou Biopharma Town, we have a local heart with a global reach. We blend groundbreaking technologies with international market opportunities, while adapting to the fast-paced biotech evolution. Our mission is to improve global health and well-being. Uniting research and development, manufacturing, marketing, and services, we strive towards a healthier, brighter future for all.
Innovate to empower, we forge a brighter future for patients. With an unwavering commitment to improving health worldwide, we redefine treatment landscapes to fulfill clinical needs, safeguarding the well-being and the lives of all.
● 2013: Company founded
● 2014: R&D team and early laboratory established
● 2016: laboratory for complex formulations established
● 2017: Pre-A financing completed
● 2018: Collaborated with Rexahn HC0301; A-round financing completed
● 2019: Collaborated with Dr. Reddys Laboratories in the US on HC007
● 2020: Collaborated with Rexahn; acquisition of WGI company in the US; A+-round financing completed
● 2021: IND for project HC0301 cleared by US FDA ; concurrent application of project HC007 in China and Europe
● 2022: Construction of innovative nucleic acid drug manufacturing center initiated
● 2022: B+-round financing completed
● 2022: IND for project HC0009 cleared by US FDA
● 2023: HC0301 was granted orphan drug destination from US FDA
● 2024: HC0301 was approved by China NMPA for Clinical Trials
